Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 23, 2017. The report announces a significant regulatory milestone for GSK's vaccine division: the approval of Shingrix (Zoster Vaccine Recombinant, Adjuvanted) by the US Food and Drug Administration (FDA) for the prevention of shingles in adults aged 50 and older.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a current report focused on a specific product approval rather than a financial statement.
Material Changes and Product Details
- Regulatory Approval: The FDA approved Shingrix for adults aged 50+ on October 20, 2017. Canada approved the vaccine for the same indication on October 13, 2017.
- Clinical Efficacy: Pooled Phase III clinical trial results involving more than 38,000 people demonstrated efficacy greater than 90% across all age groups.
- Disease Impact: The vaccine reduces the incidence of postherpetic neuralgia (PHN), the most common complication of shingles. Shingles affects approximately 1 in 3 people in the United States.
- Product Composition: Shingrix is a non-live, recombinant subunit vaccine administered intramuscularly in two doses, utilizing the AS01B adjuvant system.
Outlook, Management Commentary, and Risks
Management Commentary: Dr. Thomas Breuer, Senior Vice President and Chief Medical Officer of GSK Vaccines, described Shingrix as a "significant scientific advancement" designed to overcome age-related declines in immunity. Luc Debruyne, President of Global Vaccines, emphasized the company's commitment to addressing gaps in adult vaccine coverage.
Outlook and Next Steps: The US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) was scheduled to vote on a recommendation for Shingrix on October 25, 2017. Following this recommendation, the vaccine was expected to be available shortly. Regulatory filings were also underway in the European Union, Australia, and Japan.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ due to risks described in the company's Annual Report on Form 20-F. Specific product risks include allergic reactions to ingredients and the fact that vaccination may not protect all individuals.
Key Facts for Investor Verification
- Confirm the timing of the ACIP recommendation vote and subsequent market launch in the US.
- Monitor the status of regulatory filings in the EU, Australia, and Japan.
- Verify the commercial uptake and reimbursement status of Shingrix compared to existing shingles vaccines.
- Review the safety profile and side effect data as real-world usage expands.